Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: A survey of Canadian physicians

Thrombosis Journal

Volumn 12, Issue 1, 2014, Pages

  Nicholls, Stuart G ^a   Brehaut, Jamie C ^a,b   Arim, Rubab G ^b   Carroll, Kelly ^b   Perez, Richard ^b   Shojania, Kaveh G ^c   Grimshaw, Jeremy M ^b,d   Poses, Roy M ^e,f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Canada   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Foundation for Integrity and Responsibility in Medicine   (United States)

^f BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CANADIAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FALL RISK; FEMALE; GENERAL PRACTITIONER; GERIATRICIAN; HEALTH CARE SURVEY; HUMAN; INTERNIST; MALE; MEDICAL HISTORY; PATIENT COMPLIANCE; PRESCRIPTION; PROFESSIONAL PRACTICE; VIGNETTE;

EID: 84902690529     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-12-13     Document Type: Article

References (49)

1. Feiüberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age, distribution, and gender of aptients with atrial fibrillation. Arch Intern Med 1995, 155:469-473.
2. Man-Son-Hing M, Laupacis A: Anticoagulant-related bleeding in older persons with atrial fibrillation. Arch Intern Med 2003, 163:1580-1586.
3. Naccarelli GV, Varker H, Lin J, Schulman KL: Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009, 104:1534-1539.
4. Schwartz NE, Aübers GW: Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. Stroke 2010, 41:1307-1309.
5. Buckingham TA, Hatala R: Antocoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002, 25:447-454.
6. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM: Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006, 119:607-615.
7. Ingelgård A, Hollowell J, Reddy P, Gold K, Tran K, Fitzmaurice D: What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire. J Thromb Thrombolysis 2006, 21:257-265.
8. Brass L, Krumholz HM, Scinto JD, Mathur D, Radford M: Warfarin use following ischemic stroke among medicare patients with atrial fibrillation. Arch Intern Med 1998, 158:2093-2100.
9. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ: Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000, 31:822-827.
10. Lane DA, Lip GYH: Barriers to antocoagulation in patients with atrial fibrilaltion: changing physician-related factors. Stroke 2008, 39:7-9.
11. Neidecker M, Patel AA, Nelson WW, Reardon G: Use of warfarin in long-term care: a systematic review. BMC Geriatr 2012, 12:14.
12. Lip GY, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ: Oral anticoagulation in atrial fibrillation: a pan-European patient survey. Eur J Intern Med 2007, 18:202-208.
13. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ: Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol 2007, 49:1561-1565.
14. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH: Underuse of oral anticoagulants in atrila fibrillation: a systematic review. Am J Med 2010, 123:638-645.
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, and the RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
16. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener H-C, Franzosi MG, Hüber K, Reilly P, Varron J, Yusuf S: Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
17. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M: Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013, 347:f5133.
18. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Hüber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI: New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012, 59:1413-1425.
19. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, for the ENGAGE AF-TIMI 48 Investigators: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
20. Furie B: Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med 2013, 369:2345-2346.
21. Man-Son-Hing M, Nichol G, Lau A, Laupacis A: Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159:677-685.
22. Gattellari M, Worthington J, Zwar N, Middleton S: Barriers to the use of anticoagulation for nonvalvular atrial fibrilaltion: a representative survey of Australian family physicians. Stroke 2008, 39:227-230.
23. Anderson N, Fuller R, Dudley N: 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM 2007, 100:263-269.
24. Pechlaner C: Anticoagulation for atrial fibrillation: underuse? Am J Med 2011, 124:e11.
25. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB: Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006, 332:141-145.
26. Tversky A, Kahneman D: Availability: a heuristic for judging frequency and probability. Cogn Psychol 1973, 5:207-232.
27. Poses RM, Anthony M: Availability, wishful thinking, and physicians' judgments for patients with suspected bacteremia. Med Decis Making 1991, 11:159-168.
28. Baczek VL, Chen WT, Kluger J, Coleman CI: Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract 2012, 13:5.
29. Dillman DA: Mail and internet surveys: the tailored design. New York: John Wiley & Sons Inc; 2000.
30. Field TS, Cadoret CA, Brown ML, Ford M, Greene SM, Hill D, Hornbrook MC, Meenan RT, White MJ, Zapka JM: Do components of the "Total Design Approach" to optimizing survey response rates apply to physicians? Med Care 2002, 40:596-606.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford M: Validation of clinical classification schemes for predicting stroke results from the national registry of atrial fibrillation. JAMA 2001, 285:2864-2870.
32. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000, 150:41-46.
33. Beyth RJ, Antani MR, Covinsky KE, Miller DG, Chren M-M, Quinn LM, Landefeld CS: Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996, 11:721-728.
34. Gattellari M, Zwar NA, Worthington JM, Middleton S: Barriers to using warfarin in non-valvular atrial fibrillation. BMJ 2006, 332:303-304.
35. Bungard TJ, Ghali WA, McAlister FA, Buchan AM, Cave AJ, Hamilton PG, Mitchell LB, Shuaib A, Teo KK, Tsuyuki RT: Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ 2001, 165:301-302.
36. Bungard TJ, Ghali WA, McAlister FA, Buchan AM, Cave AJ, Hamilton PG, Mitchell LB, Shuaib A, Teo KK, Tsuyuki RT: The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol 2003, 19:280-284.
37. Peterson GM, Boom K, Jackson SL, Vial JH: Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J 2002, 32:15-23.
38. Pradhan AA, Levine MAH: Warfarin use in atrial fibrillation: a random sample survey of family physician beliefs and preferences. Can J Clin Pharmacol 2002, 9:199-202.
39. Pugh D, Pugh J, Mead GE: Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40:675-683.
40. Decker C, Garavalia L, Garavalia B, Simon T, Spertus JA, Loeb M, Daniel WC: Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc 2012, 5:129-135.
41. Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RE, Hauch O, Demers EA, Ezekowitz M: Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional study. Clin Ther 2003, 25:1751-1764.
42. Monette J, Gurwitz JH, Rochon PA, Avorn J: Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997, 45:1060-1065.
43. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest 2010, 138:1093-1100.
44. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
45. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE: A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011, 58:395-401.
46. Lip GY: Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. J Thromb Haemost 2013, 11:615-626.
47. Brehaut JC, Poses R, Shojania KG, Lott A, Man-Son-Hing M, Bassin E, Grimshaw J: Do physician outcome judgments and judgment biases contribute to inappropriate use of treatments? Study protocol. Implement Sci 2007, 2:18.
48. Elliott RH, Woodward MC, Oborne CA: Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing. Age and Aging 2002, 31:391-396.
49. Brehaut JC, Klein D, Poses R, Wigton R, Tape T, Grimshaw J, McAllister F, Nicholls S, Carroll K, Helis E: Development of a multisource feedback tool designed to increase appropriate use of treatments for atrial fibrillation among family physicians, KT Canada Summer Institute on Knowledge Translation. Hamilton, Ontario: Knowledge Translation (KT) Canada; 2013.